Form 4: Skye Bioscience Chief Medical Officer Granted Stock Options

Puneet S. Arora, Chief Medical Officer of Skye Bioscience, Inc., was granted stock options for 38,000 shares on February 24, 2025.

Summary

• Puneet S. Arora, the Chief Medical Officer of Skye Bioscience, Inc., was granted stock options.
• The transaction occurred on February 24, 2025.
• Arora received options for 38,000 shares of common stock.
• The exercise price of the stock options is $2.89.
• The options vest 25% on the one-year anniversary of February 21, 2025, and then 1/48th monthly thereafter.
• The options expire on February 25, 2035.
• Following the transaction, Arora directly owns options for 38,000 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates the company is using standard compensation practices.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules, such as the one described (25% after one year, then monthly), are typical to incentivize long-term performance.
• Comparing the size of the grant (38,000 shares) to similar companies would require analyzing Skye Bioscience's market capitalization and executive compensation strategy relative to its peers.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of investment in leadership.

Key Dates